Home LiteratureArticle Details
PMID: 23979521 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Clonal evolution in hematological malignancies and therapeutic implications.

Leukemia ·Vol. 28 ·No. 1 ·2014-01-00 ·Pages 34-43

Landau DA, Carter SL, Getz G, Wu CJ

Abstract

The ability of cancer to evolve and adapt is a principal challenge to therapy in general and to the paradigm of targeted therapy in particular. This ability is fueled by the co-existence of multiple, genetically heterogeneous subpopulations within the cancer cell population. Increasing evidence has supported the idea that these subpopulations are selected in a Darwinian fashion, by which the genetic landscape of the tumor is continuously reshaped. Massively parallel sequencing has enabled a recent surge in our ability to study this process, adding to previous efforts using cytogenetic methods and targeted sequencing. Altogether, these studies reveal the complex evolutionary trajectories occurring across individual hematological malignancies. They also suggest that while clonal evolution may contribute to resistance to therapy, treatment may also hasten the evolutionary process. New insights into this process challenge us to understand the impact of treatment on clonal evolution and inspire the development of novel prognostic and therapeutic strategies.

MeSH Terms
Evolution, Molecular Hematologic Neoplasms/genetics,pathology,therapy Humans
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Landau D A
1] Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA, USA [2] Broad Institute, Cambridge, MA, USA [3] Department of Hematology, Yale Cancer Center, New Haven, CT, USA [4] Université Paris Diderot, Paris, France.
Carter S L
Broad Institute, Cambridge, MA, USA.
Getz G
1] Broad Institute, Cambridge, MA, USA [2] Massachusetts General Hospital Cancer Center and Department of Pathology, Boston, MA, USA.
Wu C J
1] Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
References (119)
119 references, click to expand
  1. Cancer as an evolutionary and ecological process.
    Nat Rev Cancer. 2006 Dec;6(12):924-35 PMID: 17109012
  2. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse.
    J Exp Med. 2011 Apr 11;208(4):653-61 PMID: 21464223
  3. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    N Engl J Med. 2001 Apr 5;344(14):1031-7 PMID: 11287972
  4. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Blood. 2010 Nov 11;116(19):3923-32 PMID: 20693430
  5. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Blood. 2011 Dec 15;118(25):6521-8 PMID: 21931113
  6. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  7. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
    Blood. 2007 Feb 1;109(3):944-50 PMID: 17032921
  8. The evolutionary biography of chronic lymphocytic leukemia.
    Nat Genet. 2013 Mar;45(3):229-31 PMID: 23435090
  9. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.
    Oncogene. 2009 Apr 16;28(15):1807-11 PMID: 19287454
  10. Targeting BRAF for patients with melanoma.
    Br J Cancer. 2011 Feb 1;104(3):392-8 PMID: 21139585
  11. Efficient tumour formation by single human melanoma cells.
    Nature. 2008 Dec 4;456(7222):593-8 PMID: 19052619
  12. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.
    PLoS Genet. 2013;9(1):e1003137 PMID: 23326238
  13. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
    Cancer Cell. 2004 Dec;6(6):587-96 PMID: 15607963
  14. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
    Cancer Cell. 2011 Dec 13;20(6):810-7 PMID: 22137795
  15. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
    Science. 1990 Mar 2;247(4946):1079-82 PMID: 2408149
  16. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
    Cancer Res. 1987 May 15;47(10):2604-8 PMID: 3567893
  17. Adaptive therapy.
    Cancer Res. 2009 Jun 1;69(11):4894-903 PMID: 19487300
  18. Inhibition of mutated, activated BRAF in metastatic melanoma.
    N Engl J Med. 2010 Aug 26;363(9):809-19 PMID: 20818844
  19. A census of human cancer genes.
    Nat Rev Cancer. 2004 Mar;4(3):177-83 PMID: 14993899
  20. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  21. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    N Engl J Med. 2013 Jul 11;369(2):111-21 PMID: 23841729
  22. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
    N Engl J Med. 2011 Dec 29;365(26):2497-506 PMID: 22150006
  23. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    J Clin Oncol. 2008 Sep 10;26(26):4268-75 PMID: 18626007
  24. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
    Genes Dev. 2010 Aug 15;24(16):1731-45 PMID: 20713517
  25. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers.
    Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33 PMID: 19261858
  26. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.
    Cell. 1997 Mar 7;88(5):593-602 PMID: 9054499
  27. Absolute quantification of somatic DNA alterations in human cancer.
    Nat Biotechnol. 2012 May;30(5):413-21 PMID: 22544022
  28. Intratumor heterogeneity: evolution through space and time.
    Cancer Res. 2012 Oct 1;72(19):4875-82 PMID: 23002210
  29. Cellular decision making and biological noise: from microbes to mammals.
    Cell. 2011 Mar 18;144(6):910-25 PMID: 21414483
  30. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer.
    Science. 2013 Feb 1;339(6119):543-8 PMID: 23239622
  31. Many tumors in one: a daunting therapeutic prospect.
    Cancer Cell. 2011 Dec 13;20(6):695-7 PMID: 22172718
  32. Identification of selective inhibitors of cancer stem cells by high-throughput screening.
    Cell. 2009 Aug 21;138(4):645-659 PMID: 19682730
  33. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.
    Science. 2008 Nov 28;322(5906):1377-80 PMID: 19039135
  34. Human cancers express mutator phenotypes: origin, consequences and targeting.
    Nat Rev Cancer. 2011 Jun;11(6):450-7 PMID: 21593786
  35. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.
    PLoS Genet. 2012;8(2):e1002533 PMID: 22359517
  36. The origin and evolution of mutations in acute myeloid leukemia.
    Cell. 2012 Jul 20;150(2):264-78 PMID: 22817890
  37. Genomic aberrations and survival in chronic lymphocytic leukemia.
    N Engl J Med. 2000 Dec 28;343(26):1910-6 PMID: 11136261
  38. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
    Blood. 1992 Dec 15;80(12):2983-90 PMID: 1467514
  39. Genetic clonal diversity predicts progression to esophageal adenocarcinoma.
    Nat Genet. 2006 Apr;38(4):468-73 PMID: 16565718
  40. A comprehensive catalogue of somatic mutations from a human cancer genome.
    Nature. 2010 Jan 14;463(7278):191-6 PMID: 20016485
  41. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
    Cancer Cell. 2002 Aug;2(2):117-25 PMID: 12204532
  42. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
    Blood. 2012 Aug 2;120(5):1060-6 PMID: 22529291
  43. Genetic variegation of clonal architecture and propagating cells in leukaemia.
    Nature. 2011 Jan 20;469(7330):356-61 PMID: 21160474
  44. CLL clonal heterogeneity: an ecology of competing subpopulations.
    Blood. 2012 Nov 15;120(20):4117-8 PMID: 23160186
  45. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
    N Engl J Med. 2009 Jul 9;361(2):123-34 PMID: 19553641
  46. Cancer stem cells: mirage or reality?
    Nat Med. 2009 Sep;15(9):1010-2 PMID: 19734877
  47. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
    N Engl J Med. 2012 Mar 8;366(10):883-892 PMID: 22397650
  48. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  49. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.
    Nat Rev Cancer. 2012 Sep;12(9):587-98 PMID: 22918414
  50. Lessons from the past: evolutionary impacts of mass extinctions.
    Proc Natl Acad Sci U S A. 2001 May 8;98(10):5393-8 PMID: 11344284
  51. Prognostic significance of copy-number alterations in multiple myeloma.
    J Clin Oncol. 2009 Sep 20;27(27):4585-90 PMID: 19687334
  52. The role of genetic diversity in cancer.
    J Clin Invest. 2010 Feb;120(2):401-3 PMID: 20101092
  53. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
    N Engl J Med. 2012 Mar 22;366(12):1079-89 PMID: 22417203
  54. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing.
    Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 PMID: 18723673
  55. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.
    Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22745-50 PMID: 21149740
  56. Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation.
    Biol Blood Marrow Transplant. 2011 Oct;17(10):1450-1459.e1 PMID: 21781950
  57. An evolutionary model for initiation, promotion, and progression in carcinogenesis.
    Int J Oncol. 2008 Apr;32(4):729-37 PMID: 18360700
  58. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
    Cancer Res. 2006 Aug 15;66(16):7854-8 PMID: 16912157
  59. The cancer stem cell: premises, promises and challenges.
    Nat Med. 2011 Mar;17(3):313-9 PMID: 21386835
  60. The molecular basis of common and rare fragile sites.
    Cancer Lett. 2006 Jan 28;232(1):13-26 PMID: 16236432
  61. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
    Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28 PMID: 20227509
  62. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  63. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.
    Blood. 2013 Feb 28;121(9):1604-11 PMID: 23297126
  64. Apoptotic cell death induced by c-myc is inhibited by bcl-2.
    Nature. 1992 Oct 8;359(6395):552-4 PMID: 1406975
  65. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
    N Engl J Med. 2004 Aug 12;351(7):657-67 PMID: 15306667
  66. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
    J Natl Cancer Inst. 1999 May 19;91(10):861-8 PMID: 10340906
  67. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
    N Engl J Med. 2013 May 30;368(22):2059-74 PMID: 23634996
  68. The landscape of somatic copy-number alteration across human cancers.
    Nature. 2010 Feb 18;463(7283):899-905 PMID: 20164920
  69. Clonal architecture of secondary acute myeloid leukemia.
    N Engl J Med. 2012 Mar 22;366(12):1090-8 PMID: 22417201
  70. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.
    Cell. 2010 Jan 8;140(1):62-73 PMID: 20074520
  71. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm.
    Cell. 2012 Mar 2;148(5):873-85 PMID: 22385957
  72. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Blood. 2002 Aug 1;100(3):1014-8 PMID: 12130516
  73. Tumor heterogeneity and the biology of cancer invasion and metastasis.
    Cancer Res. 1978 Sep;38(9):2651-60 PMID: 354778
  74. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.
    Cell. 2009 Sep 18;138(6):1083-95 PMID: 19766563
  75. Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
    Biol Blood Marrow Transplant. 2010 Dec;16(12):1649-57 PMID: 20558312
  76. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  77. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    N Engl J Med. 2001 Apr 5;344(14):1038-42 PMID: 11287973
  78. Evolutionary dynamics of biological games.
    Science. 2004 Feb 6;303(5659):793-9 PMID: 14764867
  79. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis.
    Nature. 2009 May 21;459(7245):428-32 PMID: 19363473
  80. Clonal competition with alternating dominance in multiple myeloma.
    Blood. 2012 Aug 2;120(5):1067-76 PMID: 22498740
  81. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.
    Cancer Res. 2004 May 15;64(10):3414-27 PMID: 15150093
  82. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
    Clin Cancer Res. 2009 Jul 15;15(14):4622-9 PMID: 19584161
  83. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
    Haematologica. 2011 Aug;96(8):1161-9 PMID: 21546498
  84. Tumour evolution inferred by single-cell sequencing.
    Nature. 2011 Apr 7;472(7341):90-4 PMID: 21399628
  85. Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis.
    Leukemia. 2013 Dec;27(12):2376-9 PMID: 23612016
  86. Resistance to therapy caused by intragenic deletion in BRCA2.
    Nature. 2008 Feb 28;451(7182):1111-5 PMID: 18264088
  87. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns.
    Blood. 2012 Nov 15;120(20):4191-6 PMID: 22915640
  88. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.
    Cell. 2012 Mar 2;148(5):886-95 PMID: 22385958
  89. Cancer stem cells: back to Darwin?
    Semin Cancer Biol. 2010 Apr;20(2):65-70 PMID: 20359535
  90. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Cancer Res. 2012 Feb 1;72(3):779-89 PMID: 22180495
  91. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
    Blood. 2013 Feb 21;121(8):1403-12 PMID: 23243274
  92. The microenvironment in mature B-cell malignancies: a target for new treatment strategies.
    Blood. 2009 Oct 15;114(16):3367-75 PMID: 19636060
  93. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells.
    Nature. 2013 Jun 13;498(7453):236-40 PMID: 23685454
  94. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
    Transplantation. 2012 Apr 15;93(7):744-9 PMID: 22314337
  95. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor.
    Proc Natl Acad Sci U S A. 1982 Sep;79(18):5547-51 PMID: 6957880
  96. The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
    Nature. 2012 Apr 04;486(7403):395-9 PMID: 22495314
  97. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia.
    Cancer Genet. 2011 Dec;204(12):654-65 PMID: 22285017
  98. Collateral damage from antigen receptor gene diversification.
    Cell. 2008 Dec 12;135(6):1009-12 PMID: 19070571
  99. The genetic architecture of multiple myeloma.
    Nat Rev Cancer. 2012 Apr 12;12(5):335-48 PMID: 22495321
  100. DNA methylation: roles in mammalian development.
    Nat Rev Genet. 2013 Mar;14(3):204-20 PMID: 23400093
  101. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.
    Nat Rev Cancer. 2012 Jun 14;12(7):487-93 PMID: 22695393
  102. IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia.
    Br J Haematol. 2006 Apr;133(1):50-8 PMID: 16512828
  103. Detection of mutations in EGFR in circulating lung-cancer cells.
    N Engl J Med. 2008 Jul 24;359(4):366-77 PMID: 18596266
  104. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
  105. Accumulation of driver and passenger mutations during tumor progression.
    Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50 PMID: 20876136
  106. Advances in understanding cancer genomes through second-generation sequencing.
    Nat Rev Genet. 2010 Oct;11(10):685-96 PMID: 20847746
  107. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.
    Blood. 2012 Nov 22;120(22):4407-17 PMID: 22932801
  108. Exome sequencing in tracking clonal evolution in multiple myeloma following therapy.
    Leukemia. 2013 Apr;27(5):1188-91 PMID: 23147253
  109. Filtering transcriptional noise during development: concepts and mechanisms.
    Nat Rev Genet. 2006 Jan;7(1):34-44 PMID: 16369570
  110. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Leuk Res. 2004 May;28 Suppl 1:S47-52 PMID: 15036941
  111. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.
    Cell. 2013 Feb 14;152(4):714-26 PMID: 23415222
  112. The life history of 21 breast cancers.
    Cell. 2012 May 25;149(5):994-1007 PMID: 22608083
  113. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.
    Haematologica. 2007 Sep;92(9):1242-5 PMID: 17666364
  114. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.
    Blood. 2009 Nov 26;114(23):4832-42 PMID: 19789386
  115. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
    Nat Med. 2013 Mar;19(3):368-71 PMID: 23377281
  116. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
    Blood. 2002 Sep 15;100(6):1965-71 PMID: 12200353
  117. Clonal evolution in cancer.
    Nature. 2012 Jan 18;481(7381):306-13 PMID: 22258609
  118. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
    Nature. 2012 Jan 11;481(7382):506-10 PMID: 22237025
  119. U-2932: two clones in one cell line, a tool for the study of clonal evolution.
    Leukemia. 2013 Apr;27(5):1155-64 PMID: 23295736
Article Info
Journal
Leukemia
Abbr.
Leukemia
ISSN
1476-5551
DOI
10.1038/leu.2013.248
Published
2014-01-00
Epub
2013-00-27
Pages
34-43
Language
English
Region
England
NLM ID
8704895
PMCID
PMC3934006
Subset
IM
Grants
NHLBI NIH HHS · 1R01HL103532-01 · United States
NHGRI NIH HHS · U54 HG003067 · United States
NHLBI NIH HHS · R01 HL103532 · United States
NHGRI NIH HHS · U54HG003067 · United States
NHLBI NIH HHS · 1R01HL116452-01 · United States
NCI NIH HHS · R01 CA155010 · United States
NCI NIH HHS · 1R01CA155010-01A1 · United States
NHLBI NIH HHS · R01 HL116452 · United States
External Links
PubMed source DOI: 10.1038/leu.2013.248 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2